SEC Form 4 · accession 0001144204-17-011838
Cytosorbents Corp · CTSO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Hawes Bartlett
Officer — Chief Medical Officer
Period of report
Feb 24, 2017
Accepted (ET)
Feb 28, 2017 · 5:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175151
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $5.60 | Feb 24, 2017 | A | 20,000 | A | — | Feb 24, 2017 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Such options were granted pursuant to the CytoSorbents Corporation 2014 Long-Term Incentive Plan, and shall vest upon achievement of certain performance goals as determined in the discretion of the Board of Directors of CytoSorbents Corporation.